Hyperprolactinémie transitoire secondaire aux benzodiazépines : à propos d’un cas (notice n° 274528)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03181cam a2200301 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250117193013.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Blandin, Lucie |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Hyperprolactinémie transitoire secondaire aux benzodiazépines : à propos d’un cas |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2020.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 59 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | RésuméL’hyperprolactinémie est fréquente et représente 20 à 25 % des causes d’aménorrhée secondaire. Nous rapportons ici un cas d’hyperprolactinémie modérée observé chez une patiente de 40 ans consultant pour spanioménorrhées et douleurs inguinales dans un contexte de bartholinite. Après élimination des causes connues d’hyperprolactinémie, la prise médicamenteuse d’alprazolam est finalement incriminée. Cette notion d’hyperprolactinémie est retrouvée dans quelques études bibliographiques et figure aussi dans le résumé des caractéristiques du produit (RCP). Cependant, les benzodiazépines ne sont pas connues comme hyperprolactinémiantes dans la pratique des endocrinologues et ne figurent pas dans la liste des médicaments établie par le consensus d’experts de la Société française d’endocrinologie. Cet article a pour objectif de sensibiliser les cliniciens prescripteurs et les biologistes médicaux à la survenue possible d’une hyperprolactinémie chez les patients traités par benzodiazépines, d’autant plus que la prise de cette molécule est particulièrement fréquente en France qu’il s’agisse d’une prescription médicale ou d’une automédication. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Hyperprolactinemia is common and accounts for 20 to 25% of secondary amenorrhea causes. Here, we report a case of moderate hyperprolactinemia observed in a 40-year-old patient consulting for spaniomenorrhea and inguinal pain during a bartholinitis episode. After eliminating all known causes of hyperprolactinemia, alprazolam intake is finally assumed. This hyperprolactinemia is found in a few bibliographic studies and is also noted in the summary of product characteristics. However, benzodiazepines are not known as hyperprolactinemia-inducing drugs by the endocrinologists and do not appear in the list of drugs established by a consensus of experts from the French Society of Endocrinology. This article aims to increase awareness of prescribing physicians and biologists of the possible occurrence of hyperprolactinemia in patients treated by benzodiazepines, especially since the intake of this molecule is particularly common in France, whether it is a medical prescription or self-medication. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | hyperprolactinémie |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | benzodiazépines |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | alprazolam |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | benzodiazepines |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | hyperprolactinemia |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | alprazolam |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Siffert, Marc |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Brailova, Marina |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Sapin, Vincent |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Maqdasy, Salwan |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Oris, Charlotte |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Annales de Biologie Clinique | 78 | 4 | 2020-07-01 | p. 438-440 | 0003-3898 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-annales-de-biologie-clinique-2020-4-page-438?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-annales-de-biologie-clinique-2020-4-page-438?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux